Discover and Share the Newsletter IMODI #2 – November 201614/11/2016
Discover and Share the Newsletter IMODI #3 – March 201720/03/2017
Servier, Pierre Fabre and Sanofi acquire a new collection of patient-derived xenograft (PDX) models for their translational breast cancer research.
This new collection represents 40 established breast PDX models reflecting the 4 major molecular clinical subtypes among which 37% are triple negative, 33% are Luminal B HER2 -, 22% are Luminal B HER2+ and 8% HER2+.
All PDX models are well-characterized and annotated under harmonized procedures by the IMODI consortium.
said Alain Bruno, senior project leader, Translational and Clinical Research Oncology at Servier
This collection of very well characterized models of human breast tumours obtained using high standards provides Servier Oncology with a powerful tool that can help to reveal the potential of the compounds in the field of immunotherapy and apoptosis which are two of our main areas of research.
IMODI is now present on the Twitter and LinkedIn networks.
Follow us on @IMODI_Cancer